Most Lung Cancer Genetic Variants Are Clinically Actionable and All Patients Should Get Biomarker Testing

More than 95% of germline genetic variants identified through genetic testing in patients with lung cancer are potentially clinically actionable, researchers reported in study findings during the 2022 ASCO Plenary Series Program, leading them to recommend testing all patients with the disease.